Abstract: The invention relates to recombinant adenovirus displaying one or more heterologous epitope(s) on their fiber protein. These recombinant adenovirus are useful as vaccines for generating an immune response against said epitope(s) in individuals having a pre-existing anti-Ad immunity.
Type:
Application
Filed:
April 28, 2011
Publication date:
June 27, 2013
Applicant:
INSTITUT GUSTAVE ROUSSY
Inventors:
Karim Benihoud, Anastasia Lanzi, Michel Perricaudet
Abstract: The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition.
Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
Type:
Grant
Filed:
August 19, 2011
Date of Patent:
June 18, 2013
Assignees:
Assistance Publique-Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (Inserm), Institut Gustave-Roussy, Universite de Versailles-St Quentin en Yvelines, Universite Paris-Sud
Inventors:
William Vainchenker, Valérie Ugo, James Chloé, Jean-Pierre Le Couedic, Nicole Casadevall
Abstract: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.
Type:
Application
Filed:
December 7, 2012
Publication date:
June 13, 2013
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, VIROXIS S.A.S., INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SUD XI
Inventors:
Centre National De La Recherche Scientifique, Universite Paris-Sud XI, Institut Gustave Roussy, Viroxis S.A.S.
Abstract: The present invention concerns in vitro methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family based on a resistance expression signature, kits for performing the methods, and methods for screening or identifying a compound suitable for improving the treatment of a cancer with a molecule of the taxoid family or for reducing the resistance development during the treatment of a cancer with the molecule of the taxoid family.
Type:
Application
Filed:
April 8, 2011
Publication date:
May 23, 2013
Applicant:
INSTITUT GUSTAVE ROUSSY
Inventors:
Anne Chauchereau, Frederic Commo, Nader Al Nakouzi
Abstract: The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of a TLR3 receptor by cancer cells.
Abstract: The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition.
Type:
Application
Filed:
April 1, 2011
Publication date:
February 28, 2013
Applicant:
INSTITUT GUSTAVE ROUSSY
Inventors:
Laurence Zitvogel, Guido Kroemer, Nicolas Delahaye, Yuting Ma, Oliver Kepp
Abstract: A method for determining the benign or malignant state of a breast tumor in a biological sample is presented. The benign or malignant state is determined by measuring the variation of expression of twelve genes and at least one variant of each of the twelve genes when the variants exist, using a combination of 50 polynucleotide probe sets. An expression profile of the sample is then compared with reference expression profiles of control benign and malignant breast tissues. The probe sets can be arranged in a microarray.
Type:
Application
Filed:
July 17, 2012
Publication date:
November 8, 2012
Applicants:
INSTITUT GUSTAVE ROUSSY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Fabrice ANDRE, Stefan MICHIELS, Suzette DELALOGE, Marc SPIELMANN, Philippe DESSEN, Philippe VIELH
Abstract: The invention relates to the use of a multiplicity of polynucleotide probe sets, the multiplicity of polynucleotide probe sets consisting in a combination of pools of polynucleotide probe sets, each polynucleotide probe set containing at least one polynucleotide probe chosen among a library of nucleic acid sequences, the polynucleotide probes involved in the combination of pools of polynucleotide probe sets of the multiplicity of polynucleotide probe sets being such that each polynucleotide probe specifically hybridizes with one gene, and/or at least one of its variants when present, for determining the variation of expression at least 12 genes, and their variants when present, in order to diagnose the benign or malignant state of a breast tumor.
Type:
Grant
Filed:
January 5, 2009
Date of Patent:
October 30, 2012
Assignees:
Centre National de la Recherche Scientifique, Institut Gustave Roussy
Inventors:
Fabrice Andre, Stefan Michiels, Suzette Delaloge, Marc Spielmann, Philippe Dessen, Philippe Vielh
Abstract: The present invention relates to a mutant of MITF which is useful as a marker for predisposition to the development of cancer and to uses thereof in diagnosis and preventive treatments, sumoylation being reduced or absent in this mutant.
Type:
Application
Filed:
December 21, 2010
Publication date:
October 4, 2012
Applicants:
INSTITUT GUSTAVE ROUSSY, UNIVERSITE SOPHIA NICE ANTIPOLIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE )
Inventors:
Robert Ballotti, Corine Bertolotto, Brigitte Bressac De Paillerets, Mahaut De Lichy, Fabienne Lesueur
Abstract: The present invention relates to a method for determining the susceptibility of a patient tumor cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumor cell.
Type:
Grant
Filed:
September 7, 2007
Date of Patent:
September 11, 2012
Assignees:
Institut Gustave Roussy, INSERM (Institut National de la Sante et de la Recherche Medicale)
Abstract: Mutated viral ENV proteins having mutations in the immunosuppressive domain (ISU) of the transmembrane subunit (TM) have decreased immunosuppressive activity with respect to the wild-type ENV protein. Pharmaceutical compositions that include the protein and nucleic acids coding for the protein are also disclosed.
Type:
Application
Filed:
February 17, 2012
Publication date:
July 26, 2012
Applicants:
Institut Gustave Roussy, Universite Paris Sud X1, Centre National De La Recherche Scientifique
Abstract: The electrotransfer of a nucleic acid into tissue cells, in particular in a muscle or a tumoral tissue, is carried out by an electric stimulation of the tissue as follows: first with at least one, preferably a single, pulse of a High Voltage field strength of between 200 and 2000 volts/cm second with a single pulse of Low Voltage field strength of between 50 and 200 volts/cm and of duration of between 300 ms and 2000 ms.
Type:
Grant
Filed:
September 1, 2006
Date of Patent:
July 24, 2012
Assignees:
Bioalliance Pharma, Centre National de la Recherche Scientifique (C.N.R.S.), Institut Gustave Roussy
Abstract: The present invention relates to a polypeptide having a sequence of 7 to 20 amino acid residues, which is capable of modulating the immunosuppressive properties of a viral protein or a fragment thereof, against the host in which it is expressed (immunosuppression-modulatory sequence) when it substitutes the homologous sequence of the viral protein or fragment, the polypeptide including the minimum following consensus amino acid sequence: X1Y9Y10Y11CY12X2 wherein, X1 and X2 are selected to impact on the immunosuppressive properties, and Y9 to Y12 represent variable amino acid residues.
Type:
Grant
Filed:
March 30, 2005
Date of Patent:
May 15, 2012
Assignees:
Institut Gustave Roussy, Centre National de la Recherche Scientifique, Universite Paris Sud XI
Abstract: The present invention relates to the use of a protein phosphatase inhibitor selected from an inhibitor of the catalytic subunit of the protein phosphatase 1 (PP1), an inhibitor of GADD34 and an inhibitor of the PP1/GADD34 complex to prepare a pharmaceutical composition to prevent or treat a cancer in a mammal, wherein the pharmaceutical composition is intended for administration in combination with a product used in a treatment of a cancer.
Type:
Grant
Filed:
September 7, 2007
Date of Patent:
March 6, 2012
Assignees:
Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale (Inserm)
Abstract: The present invention relates to a prostate cancer cell line CNCM deposit number I-4126, the use thereof for preparing resistant prostate cancer cell lines, the resistant prostate cancer cell lines, and the use of these prostate cancer cell lines for screening compounds of interest.
Type:
Application
Filed:
April 12, 2010
Publication date:
February 9, 2012
Applicant:
Institut Gustave Roussy
Inventors:
Anne Chauchereau, Karim Fizazi, Catherine Gaudin, Nader Al Nakouzi, Jean Benard
Abstract: The invention is generally directed to a diagnostic method for predicting the benefit of the response of a subject diagnosed with cancer to a platinum compound-based adjuvant chemotherapy, preferably to a cisplatin-based chemotherapy which implements the determination of the MSH2 expression level in the biological sample containing tumor cells, and, optionally, the ERCC1 expression level.
Abstract: The invention relates to the use of inhibitors of the expression or the activity of scinderin and/or of ephrin-A1 inhibitors for increasing the susceptibility of tumor cells to CTL killing. Such inhibitors may be for instance interfering RNAs targeting the scinderin gene and/or interfering RNAs targeting the ephrin-A1 gene.
Type:
Grant
Filed:
December 28, 2006
Date of Patent:
November 15, 2011
Assignee:
Institut Gustave Roussy
Inventors:
Salem Chouaib, Soraya Rifal, Catherine Gaudin, Fathia Mami-Chouaib
Abstract: The present invention concerns methods for assessing the sensibility of a subject to an anticancer treatment, for screening compounds which are useful for treating a cancer and for determining the likelihood of a metastatic relapse in a subject. The methods are based on the finding that a non-functional P2X7-elicited NALP3 inflammasome pathway in a subject is indicative of a resistance to treatment. The invention further concerns methods for treating a cancer and for restoring the sensitivity of the subject to a cancer treatment.
Type:
Application
Filed:
November 27, 2008
Publication date:
September 22, 2011
Applicants:
INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE PARIS-SUD XI
Inventors:
Lionel Apetoh, Antoine Tesniere, François Ghiringhelli, Laurence Zitvogel, Guido Kroemer
Abstract: The present invention concerns in vitro methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family based on a resistance expression signature, kits for performing the methods, and methods for screening or identifying a compound suitable for improving the treatment of a cancer with a molecule of the taxoid family or for reducing the resistance development during the treatment of a cancer with the molecule of the taxoid family.
Type:
Application
Filed:
October 2, 2009
Publication date:
July 21, 2011
Applicants:
Inserm (Institut National de la Sante et de la Recherche Medicale), Institut Gustave Roussy